A Look Into Industrials Sector Value Stocks

Understanding Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies…

Understanding Value Stocks

A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.

Benzinga Insights has compiled a list of value stocks in the industrials sector that may be worth watching:

  1. Mueller Industries (NYSE:MLI) – P/E: 6.15
  2. Lightning eMotors (NYSE:ZEV) – P/E: 0.94
  3. Globus Maritime (NASDAQ:GLBS) – P/E: 0.58
  4. Encore Wire (NASDAQ:WIRE) – P/E: 5.21
  5. Eneti (NYSE:NETI) – P/E: 3.58

Most recently, Mueller Industries reported earnings per share at $2.46, whereas in Q3 earnings per share sat at $2.74. The company’s most recent dividend yield sits at 1.61%, which has decreased by 0.01% from 1.62% last quarter.

Lightning eMotors has reported Q3 earnings per share at $-0.28, which has decreased by 33.33% compared to Q2, which was -0.21. Globus Maritime’s earnings per share for Q3 sits at $0.21, whereas in Q2, they were at 0.54. Encore Wire saw a decrease in earnings per share from 9.97 in Q3 to $8.28 now. Most recently, the company reported a dividend yield of 0.04%, which has decreased by 0.02% from last quarter’s yield of 0.06%.

Eneti saw a decrease in earnings per share from 0.73 in Q3 to $0.32 now. Its most recent dividend yield is at 0.41%, which has decreased by 0.04% from 0.45% in the previous quarter.

The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

Total
0
Shares
Related Posts
Read More

Harpoon Therapeutics Announced Confirmed Response Rate 35% (11/31), Across All Tumor Types And Patient Cohorts Treated With 1 Mg Priming Dose, Including Three Confirmed, Complete Responses In Phase 1/2 Clinical Trial of T Cell Engager HPN328

Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the updated interim monotherapy data from its Phase 1/2 clinical trial evaluating

HARP